Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant chimeric anti-CD20 mAb + CHOP vs MabThera + CHOP in CD20+ DLBCL (China, Phase III)
CTR20191124Phase 3Completed
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Shanghai Institute of Biological Products. Started Jul 2019; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20191124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191124.